Drug Trial Radar · NCT03676140
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Last checked: Nov 19, 2026Latest source record: Feb 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,000
Actual
Start
Oct 1, 2018
Primary completion
Dec 15, 2018
Study completion Jan 1, 2019
Sponsor
- Lead sponsor
- Lihir Medical CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- London School of Hygiene and Tropical Medicine
- First posted
- Sep 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF. Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole community. Communities will be randomised to receive either treatment with IDA and Azithromycin on the same day or separately. Active monitoring for adverse events will be conducted and the frequency of adverse events compared between individuals receiving combined MDA or separate MDA.
Conditions
- Trachoma
- Yaws
- Lymphatic Filariases
- Scabies
- Strongyloidiasis
Interventions
Albendazole on Day 1Drug
Albendazole 400 mg oral tablet Single Dose Treatment on D1
Ivermectin on Day 1Drug
Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
Diethylcarbamazine on day 1Drug
Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
Azithromycin on Day 1Drug
Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
Azithromycin on Day 8Drug
Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Self Reported Adverse EventTime frame: 7 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Namatanai Hospital
Namatanai, Papua New Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.